L-Lysine Butyrate Composition for Palatable Solid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current butyrate administration methods, such as butyric acid, sodium butyrate, and tributyrin, face challenges with unpleasant odor and taste, rapid plasma clearance, and difficulty in handling, storage, and effective dosing due to poor organoleptic properties.
Innovation Solution
L-lysine butyrate is used as a stable, solid form that does not have an unpleasant odor or taste, allowing for easy handling and administration in larger amounts, providing higher C max, t 1/2, and AUC values compared to other butyrate supplements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If butyric acid, sodium butyrate, or tributyrin are used for butyrate administration, then butyrate delivery is achieved, but unpleasant odor and taste occur along with difficulty in handling and storage
Solution Approach 1:
The patent uses L-lysine as an intermediary substance to deliver butyrate. L-lysine butyrate serves as a mediator that combines the butyrate anion with the L-lysine cation, providing a palatable and odorless delivery system that resolves the organoleptic problems of direct butyrate administration while maintaining effective butyrate delivery to the body
Solution Approach 2:
The patent changes the chemical form of butyrate from free acid or simple salts to an amino acid salt (L-lysine butyrate). This parameter change in chemical structure fundamentally alters the organoleptic properties, eliminating unpleasant odor and taste while maintaining the therapeutic butyrate delivery function
2Reliability
If butyric acid or tributyrin are administered, then butyrate is delivered to the body, but rapid plasma clearance occurs reducing effectiveness
Solution Approach 1:
The patent changes the chemical form of butyrate to L-lysine butyrate, which modifies the pharmacokinetic parameters. This structural change results in reduced plasma clearance and extended duration of action, allowing butyrate to remain effective in the bloodstream for longer periods and improving overall therapeutic reliability
3Reliability
If butyric acid is used for butyrate supplementation, then butyrate effects are achieved, but handling, storage, and dosing become difficult
Solution Approach 1:
The patent transforms butyrate from a volatile liquid acid into a stable solid amino acid salt. This parameter change in physical state and chemical structure makes the compound easy to handle, store, and dose accurately, while maintaining effective butyrate supplementation capabilities
Solution Approach 2:
L-lysine butyrate provides a stable, non-volatile form that can be easily manufactured and distributed as a practical supplement product, replacing the difficult-to-handle butyric acid while maintaining therapeutic effectiveness
Data Source
AI summary
A food product comprises L-lysine butyrate. The food product does not contain gluten and/or is not a baked product. Alternatively, the product is an oral dosage form comprising 25 mg to 5.0 g L-lysine butyrate. The oral dosage form is a tablet, a capsule, or a sealed packet containing powder. In another alternative, orally administering L-lysine butyrate may be used to: supplementing butyrate, provide a nootropic effect, treat a condition, losing weight, improve cognition, induce or maintain ketosis, improve athletic performance, or treat or mitigate mild-to-moderate pain.